Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant

Lendava Biologics Facility Is Expected To Become Fully Operational By 2026

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.

Sandoz logo on building
Sandoz has unveiled plans to invest at least $400m in a biologics production facility in Slovenia • Source: Shutterstock

Sandoz has revealed plans to invest at least $400m to build a new biologics production plant in Lendava, Slovenia, after signing a memorandum of understanding for what has been described as one of the largest ever international private-sector investments in the country. Work on the facility is set to begin this year, with full operations at the plant “provisionally” planned for late 2026.

Citing an “increasing global demand for biosimilar medicines,” Sandoz said the investment “underpins Sandoz’s ambition to drive future growth of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business